We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.
- Authors
Pere, Helene; Tanchot, Corinne; Bayry, Jagadeesh; Terme, Magali; Taieb, Julien; Badoual, Cecile; Adotevi, Olivier; Merillon, Nathalie; Marcheteau, Elie; Quillien, Ve Ronique; Banissi, Claire; Carpentier, Alain; Sandoval, Federico; Nizard, Mevyn; Quintin-Colonna, Françoise; Kroemer, Guido; Fridman, Wolf H; Zitvogel, Laurence; Oudard, Ste Phane; Tartour, Eric
- Abstract
CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) have emerged as a dominant T cell population inhibiting anti-tumor effector T cells. Initial strategies used for Treg-depletion (cyclophosphamide, anti-CD25 mAb…) also targeted activated T cells, as they share many phenotypic markers. Current, ameliorated approaches to inhibit Treg aim to either block their function or their migration to lymph nodes and the tumor microenvironment. Various drugs originally developed for other therapeutic indications (anti-angiogenic molecules, tyrosine kinase inhibitors,etc) have recently been discovered to inhibit Treg. These approaches are expected to be rapidly translated to clinical applications for therapeutic use in combination with immunomodulators.
- Publication
Oncoimmunology, 2012, Vol 1, Issue 3, p326
- ISSN
2162-4011
- Publication type
Journal Article
- DOI
10.4161/onci.18852